Preclinical Prediction of Resistance Mutations and Proposal of Sequential Treatment Strategies for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors
Sign Up to like & getrecommendations! Published in 2025 at "Pharmaceutical Research"
DOI: 10.1007/s11095-025-03916-1
Abstract: Anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 5% of non-small cell lung cancers (NSCLCs). Although ALK tyrosine kinase inhibitors provide substantial clinical benefits, acquired resistance-conferring mutations frequently emerge, leading to disease progression. Preclinical… read more here.
Keywords: resistance; alk inhibitors; preclinical prediction; resistance mutations ... See more keywords